I

Intellia Therapeutics, Inc. Tech Stack

CRISPR/Cas9 genome editing therapeutics in clinical launch phase

Biotechnology Research Cambridge, Massachusetts 501–1,000 employees Founded 2014 Public Company

Intellia is a public CRISPR therapeutics company moving from R&D into commercial execution—evidenced by a hiring surge (50 roles posted in 30 days) heavily skewed toward healthcare, sales, and research staff at director level. The project and pain-point mix reveals the core challenge: launching the first in vivo CRISPR therapy while solving reimbursement access, patient recruitment, and site activation bottlenecks. Tech stack (Veeva CRM, Oracle Integration Cloud, MuleSoft, Workato) suggests a biotech-standard compliance and data integration layer now being scaled for commercial operations.

Tech Stack 14 technologies

Core StackWorkato MuleSoft Informatica Excel Veeva CRM Oracle Integration Cloud Dell Boomi Azure Logic Apps CRM Windows macOS Microsoft Office Veeva Quality Vault

AdoptingAWS EMR

What Intellia Therapeutics, Inc. Is Building

◆Challenges

Reimbursement access challenges
Product launch
Navigating reimbursement for novel therapy
Barriers to site activation
Patient recruitment barriers
Access barriers
Site readiness bottlenecks
Commercializing in vivo crispr therapy
High-cost therapies
Transitioning biotech from r&d to commercial

▲Active Projects

Commercialization of lonvo-z therapy
Infusion network strategy implementation
Lonvo-z program
Access strategy execution
Clinical trial awareness and enrollment
Commercial launch of in vivo crispr therapy for hae
Nex-z program
Treatment site activation
First gene editing therapy launch
Launch readiness reviews

Hiring Activity

Accelerating100 roles · 50 in 30d

Department

Healthcare

30

Research

26

Sales

26

Ops

6

Finance

2

Commercial

1

Data

1

Engineering

1

Seniority

Director

42

Senior

34

Mid

14

Lead

4

VP

2

Manager

1

Notable leadership hires: National Account Director, Patient Access Director, Strategic Accounts Director, Strategic Account Director, Area Sales Lead

Company intelligence

Find more companies like Intellia Therapeutics, Inc. by tech stack, pain points and active projects

Get started free

About Intellia Therapeutics, Inc.

Intellia Therapeutics, founded in 2014 and headquartered in Cambridge, Massachusetts, develops potentially curative treatments using CRISPR/Cas9 genome editing. The company targets severe and life-threatening diseases with the goal of providing single-course curative options by permanently editing disease-associated genes. With 501–1,000 employees, Intellia is in active clinical and early commercial stage, with recent projects focused on the launch of its first in vivo CRISPR therapy for HAE (hereditary angioedema) and the commercialization of Lonvo-Z. The organization is U.S.-based and rapidly expanding its commercial and clinical operations.

HeadquartersCambridge, Massachusetts

Company Size501–1,000 employees

Founded2014

Hiring MarketsUnited States

Frequently Asked Questions

What is Intellia Therapeutics working on?

Intellia is commercializing its first in vivo CRISPR therapy for hereditary angioedema (HAE) and advancing the Lonvo-Z and Nex-Z programs. Active work includes launch readiness, infusion network strategy, patient access, and clinical trial enrollment.